Sinovac Biotech Ltd.
SVA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $19 | $1 |
| % Growth | -70% | -92.3% | 3,694.4% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $0 |
| Gross Profit | $0 | $1 | $18 | $0 |
| % Margin | 59.5% | 54.1% | 94.5% | 86.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $1 | $0 |
| SG&A Expenses | $0 | $1 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $0 |
| Operating Income | -$1 | -$0 | $18 | $0 |
| % Margin | -122% | -31.2% | 90.6% | 42.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | $0 | $18 | $0 |
| Tax Expense | $0 | -$0 | $3 | $0 |
| Net Income | -$0 | $0 | $8 | $0 |
| % Margin | -22.3% | 7.6% | 43.7% | 21.6% |
| EPS | -1.06 | 1.08 | 85.2 | 1.06 |
| % Growth | -198.1% | -98.7% | 7,937.7% | – |
| EPS Diluted | -1.06 | 1 | 74.27 | 0.97 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | $18 | $0 |
| % Margin | -1.3% | 12.3% | 91.1% | 43.4% |